Influence of Angiotensin II receptors blocking on overall left ventricle’s performance of patients with acute myocardial infarction of limited extent. Echocardiographic assessment

  • Nearchos S. Nearchou
  • Alexandros K. Tsakiris
  • Maria D. Lolaka
  • Emmanouil N. Karatzis
  • Ioannis N. Tsiafoutis
  • Constantina D. Flessa
  • Dimitrios T. Bogiatzis
  • Ilias Zarcos
  • Panagiotis D. Skoufas
Article

Abstract

Introduction

Recent studies documented the beneficial effect of angiotensin-receptor blockers (ARBs) on patients (pts) with acute myocardial infarction (AMI) combined with left ventricle (LV) systolic dysfunction. The present study intended to assess the impact of the ARB irbesartan, on the overall LV performance in pts with uncomplicated AMI of limited extent.

Methods

Forty consecutive pts with first inferior AMI (AMI-I) and preserved LV-systolic function were enrolled. They were allocated into two groups: (a) 20 pts received the conventional treatment of AMI-I and placebo (CT) and (b) 20 pts administered irbesartan additionally to the conventional treatment (IR). Twenty four healthy individuals of matching age and sex were recruited as control group (CG). Complete echocardiographic examination, Tei index of overall LV function and systolic blood pressure (SBP) were measured on the 8th post-infarct day.

Results

The Tei index of IR group (0.53±0.03) was significantly lower compared to that of CT group (0.78±0.05) (p<0.001) and was similar to that of CG (0.45±0.03)(p=NS). Irbesartan induced a considerable decrease in both isovolumic relaxation (115±7 ms vs 140±7 ms; p<0.01) and contraction time (52±2 ms vs 64±3 ms; p<0.01) and a significant increase in ejection time (279±6 ms vs 256±8 ms; p<0.05). SBP in pts of IR group was similar to that of CT group (112±3 mmHg vs 113±4 mmHg; p=NS).

Conclusions

Therapy with Irbesartan improves overall LV function of pts with AMI-I. Irbesartan leads to acceleration of the LV relaxation, which possibly indirectly ameliorates LV systolic performance too. This beneficial influence is possible attributed to a direct tissue effect of the drug and not to its hemodynamic action.

Keywords

Acute myocardial infarction of limited extent Irbesartan Tei index 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pfeffer M, Braunwald E, Moye L, et al. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327:369–77PubMedCrossRefGoogle Scholar
  2. 2.
    Pfeffer M, Lamas G, Vaughan D, Parisi A, Braunwald E. (1988). Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319:80–6PubMedCrossRefGoogle Scholar
  3. 3.
    Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. (1991). Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting-enzyme inhibition. Lancet 337:872–6CrossRefPubMedGoogle Scholar
  4. 4.
    The Acute Infarction Ramipril Efficacy (AIRE) (1993). Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821–8Google Scholar
  5. 5.
    Grouppo Italiano per Io Studio della Streptochinasi nell’ Infarcto Miocardico. (1994). GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction. Lancet 343:1115–21Google Scholar
  6. 6.
    Goodfriend T, Elliott M, Catt K. (1996). Angiotensin receptors and their antagonists. N Engl J Med 334:1649–54CrossRefPubMedGoogle Scholar
  7. 7.
    Petrie M, Padmanabhan N, McDonald J, Hillier C, Connell J, McMurray J. (2001). Angiotensin converting enzyme (ACE) and non ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 37:1056–61CrossRefPubMedGoogle Scholar
  8. 8.
    Stumpe K, Haworth D, Hoglund C, et al. (1998). Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press 7:31–7CrossRefPubMedGoogle Scholar
  9. 9.
    St John’s University College of Pharmacy, 8000 Utopia Parkaway, NY 11439. (2001). USA: Angiotensin II receptor blockers for the treatment of hypertension. Expert Opin Pharmacother 2:1795–804CrossRefGoogle Scholar
  10. 10.
    Pitt B, Segal R, Martinez F, et al. (1997). Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–52CrossRefPubMedGoogle Scholar
  11. 11.
    Pitt B, Poole-Wilson P, Segal R, et al. (1999). Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design and baseline characteristics of patients in the Losartan Heart Failure Survival Study- ELITE II. J Card Fail 5:146–54CrossRefPubMedGoogle Scholar
  12. 12.
    Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. (2001). Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effects of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–8CrossRefPubMedGoogle Scholar
  13. 13.
    Lewis E, Hunsicker L, Clarke W, et al. (2001). Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–60CrossRefPubMedGoogle Scholar
  14. 14.
    Dickstein K, Kjekshus J. (2002). Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 360:752–60CrossRefPubMedGoogle Scholar
  15. 15.
    Preffer M, McMurray J, Velazquez E, et al. (2003). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (VALsartan In Acute myocardial iNfarcTion, VALIANT). N Engl J Med 349:1893–906CrossRefPubMedGoogle Scholar
  16. 16.
    Rakowski H, Appleton C, Chan K, et al. (1996). Canadian Consensus Recommendations for the Measurement and Reporting of Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr 9:736–60CrossRefPubMedGoogle Scholar
  17. 17.
    Rokey R, Kuo L, Zoghbi W, et al. (1985). Determination of parameters of left ventricular diastolic filling with pulsed Doppler echocardiography: comparison with cineangiography. Circulation 71:543–50PubMedGoogle Scholar
  18. 18.
    Spirito P, Maron B, Bonow R. (1986). Noninvasive assessment of left ventricular diastolic function: comparative analysis of Doppler echocardiography and radionuclide angiographic techniques. J Am Coll Cardiol 7:518–25PubMedCrossRefGoogle Scholar
  19. 19.
    Dujardin K, Tei C, Yeo T, Hodge D, Rossi A, Seward J. (1998). Prognostic value of a doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol 82:1071–76CrossRefPubMedGoogle Scholar
  20. 20.
    Bruch C, Schmermund A, Marin D, et al. (2000). Tei index in patients with mild to moderate congestive heart failure. Eur Heart J 21:1888–95CrossRefPubMedGoogle Scholar
  21. 21.
    Lacorte J, Cabreriza S, Rabkin D, et al. (2003). Correlation of the tei index with invasive measurements of ventricular function in a porcine model. J Am Soc Echocardiogr 16:442–7CrossRefPubMedGoogle Scholar
  22. 22.
    Nearchou N, Tsakiris A, Lolaka M, Zarcos I, Skoufas D, Skoufas P. (2003). Influence of perindopril on left ventricular global performance during the early phase of inferior acute myocardial infarction: assessment by Tei index. Echocardiography 20:319–27CrossRefPubMedGoogle Scholar
  23. 23.
    Poulsen S, Jensen S, Tei C, Seward J, Egstrup K. (2000). Value of the Doppler Index of Myocardial Performance in the Early Phase of Acute Myocardial Infarction. J Am Soc Echocardiogr 13:723–30CrossRefPubMedGoogle Scholar
  24. 24.
    Jugdutt B. (1993). Prevention of ventricular remodelling post myocardial infarction: timing and duration of therapy. Can J Cardiol 9:103–14PubMedGoogle Scholar
  25. 25.
    Gaudron P, Eilles C, Kugler I, Ertl G. (1993). Progressive left ventricular dysfunction and remodelling after myocardial infarction. Potential mechanisms and early predictors. Circulation 87:755–63PubMedGoogle Scholar
  26. 26.
    Heikkila J, Luomanmaki K, Pyorala K. (1971). Serial observations on left ventricular dysfunction in acute myocardial infarction. II Systolic time intervals in power failure. Circulation 44:343–54PubMedGoogle Scholar
  27. 27.
    Hodges M, Halpern B, Friesinger G, Dagenais G. (1972). Left ventricular preejection period and ejection time in patients with acute myocardial infarction. Circulation 45:933–42PubMedGoogle Scholar
  28. 28.
    Moller J, Dahlstrom U, Gotzsche O et al. (2004). Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: Results of the Optimal trial in myocardial infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy. Am Heart J 147:494–501CrossRefPubMedGoogle Scholar
  29. 29.
    Moller J, Poulsen S, Egstrup K. (1999). Effect of preload alternations on a new Dopppler echocardiographic index of combined systolic and diastolic performance. J Am Soc Echocardiogr 12:1065–72CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Nearchos S. Nearchou
    • 1
  • Alexandros K. Tsakiris
    • 1
  • Maria D. Lolaka
    • 1
  • Emmanouil N. Karatzis
    • 1
  • Ioannis N. Tsiafoutis
    • 1
  • Constantina D. Flessa
    • 1
  • Dimitrios T. Bogiatzis
    • 1
  • Ilias Zarcos
    • 1
  • Panagiotis D. Skoufas
    • 1
  1. 1.1st Cardiology DepartmentHellenic Red Cross HospitalAthensGreece

Personalised recommendations